Demographics of cord blood and bone marrow recipients that contributed to the T-cell reconstitution study
| CBT (n = 30; 26 single-cord and 4 double-cord) . | BMT (n = 40) . |
|---|---|
| Age at transplant | |
| 1 y (0.1-12) | 4.3 y (0.6-12) |
| Diagnosis | |
| Acute leukemia, 12 (40%); myelodysplastic syndrome/chronic myeloid leukemia, 2 (6%); immunodeficiency, 12 (40%); hemophagocytic lymphohistiocytosis 4 (14%) | Acute leukemia, 17 (42%); myelodysplastic syndrome/chronic myeloid leukemia, 3 (8%); immunodeficiency, 13 (32%); hemophagocytic lymphohistiocytosis, 5 (13%); metabolic, 2 (5%) |
| Conditioning | |
| Myeloablative conditioning, 29 (97%; TBI or Bu-based or treosulfan-based); no conditioning, 1 (3%) | Myeloablative conditioning, 40 (100%; TBI or Bu-based or treosulfan-based) |
| HLA matching | |
| ≤8/10: 17 | 10/10: 40 |
| 9/10: 14 | |
| 10/10: 03 | |
| Acute GVHD | |
| Grade II: 10 (33%) | Grade II: 7 (18%) |
| Grade III-IV: 5 (16%) | Grade III-IV: 3 (8%) |
| Viral reactivations | |
| CMV: 4 (13%) | CMV: 7 (17%) |
| ADV: 4 (13%) | ADV: 4 (10%) |
| CBT (n = 30; 26 single-cord and 4 double-cord) . | BMT (n = 40) . |
|---|---|
| Age at transplant | |
| 1 y (0.1-12) | 4.3 y (0.6-12) |
| Diagnosis | |
| Acute leukemia, 12 (40%); myelodysplastic syndrome/chronic myeloid leukemia, 2 (6%); immunodeficiency, 12 (40%); hemophagocytic lymphohistiocytosis 4 (14%) | Acute leukemia, 17 (42%); myelodysplastic syndrome/chronic myeloid leukemia, 3 (8%); immunodeficiency, 13 (32%); hemophagocytic lymphohistiocytosis, 5 (13%); metabolic, 2 (5%) |
| Conditioning | |
| Myeloablative conditioning, 29 (97%; TBI or Bu-based or treosulfan-based); no conditioning, 1 (3%) | Myeloablative conditioning, 40 (100%; TBI or Bu-based or treosulfan-based) |
| HLA matching | |
| ≤8/10: 17 | 10/10: 40 |
| 9/10: 14 | |
| 10/10: 03 | |
| Acute GVHD | |
| Grade II: 10 (33%) | Grade II: 7 (18%) |
| Grade III-IV: 5 (16%) | Grade III-IV: 3 (8%) |
| Viral reactivations | |
| CMV: 4 (13%) | CMV: 7 (17%) |
| ADV: 4 (13%) | ADV: 4 (10%) |